(NASDAQ: NEO) Neogenomics's forecast annual revenue growth rate of 7.41% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.44%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.64%.
Neogenomics's revenue in 2025 is $709,162,000.On average, 16 Wall Street analysts forecast NEO's revenue for 2025 to be $94,786,915,257, with the lowest NEO revenue forecast at $91,685,489,667, and the highest NEO revenue forecast at $99,202,920,905. On average, 16 Wall Street analysts forecast NEO's revenue for 2026 to be $104,152,004,293, with the lowest NEO revenue forecast at $99,512,157,749, and the highest NEO revenue forecast at $109,650,985,835.
In 2027, NEO is forecast to generate $113,764,224,029 in revenue, with the lowest revenue forecast at $107,526,438,143 and the highest revenue forecast at $122,271,471,945.